Matakina and Breast Cancer Screening Programme of the French Community of Belgium Annouce Trial of Volpara Breast Density Software

Matakina International Limited of Wellington, New Zealand, today announced that it has signed an agreement with the Breast Cancer Screening Programme of the French Community of Belgium for trial of Matakina’s Volpara® breast density software.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
“The use of objective measurements will assist the radiologists and help remove the subjectivity we see in density readings," said Michael Candeur of CCR.

Wellington, New Zealand (PRWEB) May 08, 2012

Matakina International Limited of Wellington, New Zealand, today announced that it has signed an agreement with the Breast Cancer Screening Programme of the French Community of Belgium for trial of Matakina’s Volpara® breast density software.

Matakina’s Volpara breast density software is the only breast density quantification software that is CE Marked and FDA Cleared for all x-ray systems. “Volpara’s vendor neutral stance was a key factor in choosing it for this trial as we have x-ray systems of all kinds within our Breast Screening Programme, and we’re likely to be extending that range in time,” said Michel Candeur of the Centre Communautaire de Reference (CCR). “The use of objective measurements will assist the radiologists and help remove the subjectivity we see in density readings which is going to be critical as we move towards a more personalized screening experience.”

“Radiologists face immense challenges in analysing tissue density and have not had the ability to objectively and automatically quantify the actual amount of breast density from the screening mammogram,” said Dr Ralph Highnam, CEO, Matakina International, Ltd. “Among other benefits, this trial will improve radiologists’ understanding of breast density and help them in guiding patients to make appropriate screening decisions.”

Breast tissue density has not only been linked to an increased risk of breast cancer, it also decreases the sensitivity of the mammogram and thereby may impact early detection. Studies have also confirmed that as tissue density increases, the accuracy of mammography decreases. Thirty-five percent of breast cancer goes undetected by mammography in women with dense breasts, as density masks the appearance of tumors (Boyd et al 2007, NEJM).

Volpara is a reliable tool which automatically generates objective, automatic measurement of volumetric breast density values under the Volpara Density Grade (VDG®) – a refined grading system which correlates with the American College of Radiology BIRADS Density Grading Classifications. Integration of Volpara with other digital mammography systems, CAD systems and mammography reporting system are also underway.

About Matakina
Founded to enable radiologists to give women the most accurate information possible regarding their breast health, Matakina International, Limited is the wholly owned sales and marketing arm of Matakina Technology Limited of New Zealand. Volpara’s founders and Board of Directors includes John Hood, PhD, former Vice Chancellor of the University of Oxford, UK, Ralph Highnam, PhD, former CEO of Mirada Solutions, one of the University of Oxford’s most successful spin-outs of recent times and co-author of the seminal book Mammographic Image Analysis; and Professor Sir Michael Brady, a serial entrepreneur who recently retired from the University of Oxford where he was Professor of Information Technology for 25 years.

Media Contact:
Chris K. Joseph
510/435-4031
chris(at)ckjcomm(dot)com


Contact

  • David Mezzoprete
    david.mezzoprete@volparadensity.com
    585 737 0587
    Email